COVID Vaccine Maker Moderna Is S&P 500's Best Stock of 2026, Up 663%
Moderna is up 663% this year, the S&P 500's best performer, after its cancer vaccine trial with Merck passed a final-stage test.
8 h ago10 min read
Moderna is up 663% this year, the S&P 500's best performer, after its cancer vaccine trial with Merck passed a final-stage test.